Draft:LMP-102

x= LMP-102 = LMP-102 (marketed under the trademark LMP-102™, and also referred to as LMP 102) is a commercial bacteriophage-based antimicrobial food additive developed by Intralytix, Inc., a biotechnology company headquartered in Baltimore, Maryland, United States. It is a preparation of six naturally occurring, lytic bacteriophages formulated to target and kill strains of Listeria monocytogenes, a foodborne bacterial pathogen. LMP-102 is notable as the first bacteriophage-based preparation to receive approval from the United States Food and Drug Administration (FDA) for use as a food additive.

Overview

LMP-102 consists of a mixture of six distinct bacteriophages, viruses that infect and destroy specific species of bacteria without affecting human, animal, or plant cells. Each phage in the cocktail targets a different range of L. monocytogenes strains; combining multiple phages with overlapping but non-identical host ranges was intended to reduce the likelihood that the target bacteria would develop resistance to the treatment. The product is applied as a liquid spray directly onto ready-to-eat (RTE) foods., such as sliced deli meats, poultry products, and soft cheeses, as well as onto food-contact surfaces and processing equipment.

Because bacteriophages occur naturally in the environment, including in soil, water, and the human gastrointestinal tract, the product is marketed by Intralytix as an "all-natural" intervention that does not alter the taste, odor, texture, or appearance of treated foods, in contrast to chemical antimicrobial washes.

Target pathogen

Listeria monocytogenes is a gram-positive bacterium capable of causing listeriosis, a relatively rare but potentially severe foodborne illness. It disproportionately affects pregnant women, newborns, older adults, and individuals with compromised immune systems, and it is notable among foodborne pathogens for its ability to survive and multiply at refrigeration temperatures. Ready-to-eat foods, which receive no further cooking step before consumption, are a principal vehicle for listeriosis outbreaks, making post-processing interventions such as LMP-102 attractive to food manufacturers.

Development and mechanism

The bacteriophages contained in LMP-102 are propagated in Listeria host cultures during manufacturing. Because the phages are grown on the target bacterium itself, regulatory review examined whether residual bacterial components, particularly the Listeria toxin listeriolysin O (LLO), might persist in the finished product. Testing submitted to the FDA found no detectable LLO in LMP-102, and regulators further noted that any trace residue would likely be inactivated under normal digestive conditions.

The phages act through the standard lytic bacteriophage life cycle: a phage particle attaches to a susceptible Listeria cell, injects its genetic material, hijacks the cell's machinery to replicate, and ultimately causes the cell to lyse (rupture), releasing new phage particles. Because phages are generally highly specific to their bacterial hosts, LMP-102 was designed to affect only Listeria populations and not other microorganisms present in or on food.

Company-reported testing cited at the time of FDA approval indicated that LMP-102 could reduce Listeria contamination by approximately 99% to 99.9% (roughly two to three orders of magnitude, or "logs") on foods with relatively high initial contamination levels.

Regulatory approval

FDA approval (2006)

The FDA's Center for Food Safety and Applied Nutrition reviewed LMP-102 as a food additive, concluding in a memorandum dated June 3, 2005, that the preparation was safe for use on ready-to-eat meat and poultry products. On August 18, 2006, the FDA formally amended its food additive regulations (codified at 21 C.F.R. § 172.785) to permit the use of the bacteriophage preparation as an antimicrobial agent against L. monocytogenes on ready-to-eat meat and poultry. Intralytix publicly announced the approval on August 19, 2006, describing LMP-102 as the first and, at that time, only FDA-approved bacteriophage-based food safety product.

The federal regulation specifies detailed manufacturing and quality-control criteria for the additive, including that each of the six monophage components must have a mean phage titer of approximately 1 × 10⁹ plaque-forming units (PFU) per milliliter, that the phages must not carry functional toxin-encoding genetic sequences, that LLO levels must not exceed 5 hemolytic units per milliliter, and that the preparation must test negative for live L. monocytogenes and other bacterial contamination.

EPA registration (2008)

In 2008, LMP-102 additionally received registration from the U.S. Environmental Protection Agency (EPA) as an antimicrobial agent, extending its approved use beyond food products to include food-contact surfaces and processing equipment within food production facilities. Following this registration, Intralytix stated that the product could be applied to a broader range of items, including coleslaw, unpasteurized cheese, pasteurized milk, and various deli meats, as well as directly onto processing equipment, without corroding surfaces or altering the sensory qualities of treated foods

Manufacturer

Intralytix, Inc. is a biotechnology company based in Baltimore, Maryland, that specializes in the research, development, and commercialization of bacteriophage-based products for food safety, agricultural, and biomedical applications. At the time of LMP-102's approval, the company's president and chief executive officer was John Vazzana, who served as a public spokesperson for the product in industry and trade press coverage. Following the development of LMP-102, Intralytix pursued similar phage-based products targeting other major foodborne pathogens, including Escherichia coli O157:H7 and Salmonella species.

Reception and context

LMP-102's approval was widely covered in food-safety and food-industry trade publications as a milestone for the use of bacteriophage technology in commercial food production, and it is frequently cited in scientific and regulatory literature as an early example of a government-approved "biocontrol" agent for foodborne pathogens. Industry analyses at the time noted that phage-based antimicrobials such as LMP-102 entered a food-safety antimicrobial market valued in the hundreds of millions of dollars in the United States, and that such products were generally priced at a premium relative to conventional chemical sanitizers.

See also

• Bacteriophage
• Listeria monocytogenes
• Listeriosis
• Food additive
• Biocontrol of foodborne pathogens
• Intralytix